z-logo
open-access-imgOpen Access
A possible role of thymidine phosphorylase expression and5‐fluorouracil increased sensitivity in oropharyngeal cancer patients
Author(s) -
Ranieri G.,
Grammatica L.,
Patruno R.,
Zito A.F.,
Valerio P.,
Iacobellis S.,
Gadaleta C.,
Gasparini G.,
Ribatti D.
Publication year - 2007
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2007.00007.x
Subject(s) - thymidine phosphorylase , capecitabine , cd34 , fluorouracil , immunohistochemistry , medicine , angiogenesis , cancer research , cancer , oncology , biology , stem cell , colorectal cancer , genetics
Thymidine Pi deoxyribosyltransferase (TP) is an enzyme involved in DNA synthesis up‐regulated in tumours and it is also a pro‐angiogenic factor. TP cannot activate capecitabine, because capecitabine first needs conversion by carboxylesterase and cytidine deaminase into 5‐deoxy‐fluorouridine. This compound can be activated by TP to 5‐fluorouracil (5‐FU). Although TP is not necessary for 5‐FU toxicity, experimental data suggest that high levels of TP correlate with an enhanced response to 5‐FU therapy. In this study, we have analysed by immunohistochemistry CD34, CD68 and TP positive cells in bioptic samples from 53 patients with T 1–3 N 0–1 M 0 oropharyngeal squamous cell carcinoma (OSC) and from 24 patients with non‐dysplastic oropharyngeal leukoplakia (NDOLP). Results showed that the mean of TP‐positive cells, CD68 positive macrophages and CD34 positive endothelial cells eval‐uated as microvessel density (MVD) was significantly higher in OSC than in NDOLP. Moreover, at a median follow‐up of 19 months, patients with TP expression and higher MVD showed a better survival rate as compared to those with low MVD, probably as a consequence of 5‐FU‐based therapy.We hypothesized a role for TP in oropharyngeal tumourigenesis and 5‐FU activation in the adjuvant setting of OSC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here